Condition

Infection, Human Immunodeficiency Virus I

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 21 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting0
Common interventions25
Lead sponsors shown2
Advertisement

Clinical trials

21 shown
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)NCT03327740 · 2014-09-30
COMPLETED
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™NCT01597648 · 2011-11-01
COMPLETED
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.NCT01283100 · 2011-03-01
WITHDRAWN
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)NCT01263015 · 2011-02-01
COMPLETED
ZIAGEN® Post-marketing SurveillanceNCT01205243 · 2010-11-01
COMPLETED
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyNCT01227824 · 2010-10-19
COMPLETED
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive SubjectsNCT00549198 · 2007-06-01
COMPLETED
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected PatientsNCT00481390 · 2007-06-01
COMPLETED
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 InfectionNCT00440947 · 2007-03-01
COMPLETED
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive AdultsNCT00450580 · 2007-03-01
COMPLETED
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced AdultsNCT00242879 · 2005-08-01
TERMINATED
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected SubjectsNCT00197145 · 2005-07-21
TERMINATED
GW873140 In Combination With Combivir In HIV Infected SubjectsNCT00104429 · 2005-01-01
TERMINATED
Fosamprenavir Versus Other Protease InhibitorsNCT00094523 · 2004-12-14
COMPLETED
GW873140 In Combination With Kaletra In HIV Infected SubjectsNCT00102778 · 2004-12-01
TERMINATED
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected AdultsNCT00257621 · 2004-10-01
COMPLETED
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV InfectionNCT00089583 · 2004-07-01
COMPLETED
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIVNCT00082394 · 2004-04-26
COMPLETED
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)NCT00242840 · 2003-06-01
COMPLETED
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced PatientsNCT00046176 · 2002-08-26
COMPLETED
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected SubjectsNCT00044577 · 2002-07-16
COMPLETED

Common interventions

Trial status mix

COMPLETED16
TERMINATED4
WITHDRAWN1

Phase mix

PHASE39
PHASE25
PHASE12
PHASE42
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.